Macquarie Group Ltd. Trims Position in Charles River Laboratories International, Inc. $CRL

Macquarie Group Ltd. decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 12.1% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 202,141 shares of the medical research company’s stock after selling 27,950 shares during the period. Macquarie Group Ltd. owned 0.41% of Charles River Laboratories International worth $40,323,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Castleark Management LLC lifted its stake in shares of Charles River Laboratories International by 3.1% during the fourth quarter. Castleark Management LLC now owns 32,245 shares of the medical research company’s stock valued at $6,432,000 after buying an additional 980 shares during the period. Federation des caisses Desjardins du Quebec lifted its stake in shares of Charles River Laboratories International by 17.9% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 3,925 shares of the medical research company’s stock valued at $783,000 after buying an additional 596 shares during the period. DRW Securities LLC purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $211,000. Brooklyn Investment Group purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $361,000. Finally, Cibc World Markets Corp purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $1,025,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $187.39 on Friday. Charles River Laboratories International, Inc. has a one year low of $143.06 and a one year high of $228.88. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The company has a 50 day moving average price of $173.50 and a 200 day moving average price of $182.41. The firm has a market capitalization of $9.03 billion, a price-to-earnings ratio of -49.84, a price-to-earnings-growth ratio of 2.15 and a beta of 1.46.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. During the same quarter in the prior year, the business posted $2.34 earnings per share. Charles River Laboratories International’s revenue for the quarter was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.04 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CRL. Robert W. Baird set a $213.00 price objective on shares of Charles River Laboratories International in a research note on Friday, May 8th. Barclays upped their price objective on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. JPMorgan Chase & Co. reduced their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, April 13th. TD Cowen reduced their price objective on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Finally, Mizuho set a $192.00 price target on shares of Charles River Laboratories International in a research report on Friday, May 8th. Eleven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average target price of $208.50.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.